Bookmark and Share
BioAssay: AID 624421

qHTS of GLP-1 Receptor Inverse Agonists: Summary

The overall goal of this project was to develop a novel assay for discovering small molecule ligands for class B1 G protein-coupled receptors (GPCRs). Very few agonists (or inverse agonists) with generally weak activity for this entire group of physiologically important receptors are known to date. To establish proof-of-principle that this critical bottleneck can be overcome with a suitable screening approach, our studies focused on the class B1 receptor for glucagon-like peptide-1 (GLP-1R), a potential therapeutic target for diabetes and neurodegenerative disease. ..more
_
   
AID: 624421
Data Source: NCGC (GLPIA1000)
BioAssay Type: Summary, Candidate Probes/Leads with Supporting Evidence
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2012-07-30
Target
Related Experiments
AIDNameTypeComment
624152qHTS of GLP-1 Receptor Agonists: SummarySummarydepositor-specified cross reference: Summary AID for Agonists of GLP1
624417qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)Confirmatorydepositor-specified cross reference: qHTS AID
624418qHTS of GLP-1 Receptor Inverse Agonists: Cytotox ScreenConfirmatorydepositor-specified cross reference: Cytotox qHTS AID
624148qHTS of GLP-1 Receptor Agonists: LOPAC ValidationConfirmatorysame project related to Summary assay
624172qHTS of GLP-1 Receptor AgonistsConfirmatorysame project related to Summary assay
743262qHTS of GLP-1 Receptor Agonists: Hit ValidationConfirmatorysame project related to Summary assay
Description:
The overall goal of this project was to develop a novel assay for discovering small molecule ligands for class B1 G protein-coupled receptors (GPCRs). Very few agonists (or inverse agonists) with generally weak activity for this entire group of physiologically important receptors are known to date. To establish proof-of-principle that this critical bottleneck can be overcome with a suitable screening approach, our studies focused on the class B1 receptor for glucagon-like peptide-1 (GLP-1R), a potential therapeutic target for diabetes and neurodegenerative disease.

The assay was developed using a cell-based functional readout. Toward this goal, stably transfected HEK293 cell clones were established that co-express (i) a cAMP-responsive luciferase reporter gene, and (ii) constitutively active GLP-1R that upon ligand interaction inhibit (inverse agonists) the luciferase activity. In addition, two control cell lines were developed: (i) one that express only the cAMP-responsive reporter gene to enable initial exclusion of GLP-1R independent effects of candidate probes; and (ii) one with the reported gene cloned with another constitutively active orphan receptor GPR119 to enable exclusion of GLP-1R independent inhibitor effects of candidate inverse agonists.

NIH Molecular Libraries Probe Production Network [MLPCN]
NIH Chemical Genomics Center [NCGC]

Grant: NS064851
PI Name: Martin Beinborn, Tufts Medical Center
Protocol
Please see linked AIDs for detailed protocols for each respective assay.
Comment
This project is on-going and will be updated at a later point.
Categorized Comment - additional comments and annotations
From PubChem:
Assay Cell Type: HEK293
Additional Information
Grant Number: NS064851

PageFrom: